Lin Y, Berdeja J, Raje N, et al. First-in-human multicenter study of BB2121 anti-BCMA CAR T cell therapy for relapsed/refractory multiple myeloma: updated results. EHA 2017, abstract 142.
Rituximab of obinutuzumab of plus CHOP bij nieuw-gediagnostiseerd DLBCL
aug 2017 | Lymfoom